University of Kentucky

UKnowledge
Physiology Faculty Publications

Physiology

12-29-2021

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune
Cascade and Promotes Recovery after Spinal Cord Injury
Chen Guang Yu
University of Kentucky, cyu4@uky.edu

Vimala Bondada
University of Kentucky, vbond0@uky.edu

Hina Iqbal
University of Kentucky, hina.iqbal@uky.edu

Kate L. Moore
University of Kentucky, km00800@gmail.com

John C. Gensel
University of Kentucky, gensel.1@uky.edu

See next page for additional authors
Follow this and additional works at: https://uknowledge.uky.edu/physiology_facpub
Part of the Medical Immunology Commons, Neurosciences Commons, and the Physiology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Yu, Chen Guang; Bondada, Vimala; Iqbal, Hina; Moore, Kate L.; Gensel, John C.; Bondada, Subbarao; and
Geddes, James W., "Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes
Recovery after Spinal Cord Injury" (2021). Physiology Faculty Publications. 188.
https://uknowledge.uky.edu/physiology_facpub/188

This Article is brought to you for free and open access by the Physiology at UKnowledge. It has been accepted for
inclusion in Physiology Faculty Publications by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and
Promotes Recovery after Spinal Cord Injury
Digital Object Identifier (DOI)
https://doi.org/10.3390/ijms23010355

Notes/Citation Information
Published in International Journal of Molecular Sciences, v. 23, issue 1, 355.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Authors
Chen Guang Yu, Vimala Bondada, Hina Iqbal, Kate L. Moore, John C. Gensel, Subbarao Bondada, and
James W. Geddes

This article is available at UKnowledge: https://uknowledge.uky.edu/physiology_facpub/188

International Journal of

Molecular Sciences
Article

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune
Cascade and Promotes Recovery after Spinal Cord Injury
Chen Guang Yu 1, *, Vimala Bondada 1 , Hina Iqbal 1 , Kate L. Moore 1 , John C. Gensel 2 , Subbarao Bondada 3
and James W. Geddes 1, *
1

2

3

*



Citation: Yu, C.G.; Bondada, V.; Iqbal,
H.; Moore, K.L.; Gensel, J.C.;
Bondada, S.; Geddes, J.W. Inhibition
of Bruton Tyrosine Kinase Reduces
Neuroimmune Cascade and
Promotes Recovery after Spinal Cord
Injury. Int. J. Mol. Sci. 2022, 23, 355.
https://doi.org/10.3390/ijms23010355
Academic Editors: Naren L. Banik
and Azizul Haque

Spinal Cord and Brain Injury Research Center, Department of Neuroscience, College of Medicine,
University of Kentucky, 741 S. Limestone Street, Lexington, KY 40536, USA; vbond0@uky.edu (V.B.);
hina.iqbal@uky.edu (H.I.); km00800@gmail.com (K.L.M.)
Department of Physiology, College of Medicine, University of Kentucky, 741 S. Limestone Street,
Lexington, KY 40536, USA; gensel.1@uky.edu
Department of Microbiology, Immunology & Molecular Genetics, Markey Cancer Center, College of Medicine,
University of Kentucky, 800 Rose St, Lexington, KY 40536, USA; subbarao.bondada@uky.edu
Correspondence: cyu4@uky.edu (C.G.Y.); jgeddes@uky.edu (J.W.G.);
Tel.: +1-(859)-323-8770 (C.G.Y.); +1-(859)-323-5315 (J.W.G.); Fax: +1-(859)-257-5737 (C.G.Y. & J.W.G.)

Abstract: Microglia/astrocyte and B cell neuroimmune responses are major contributors to the
neurological deficits after traumatic spinal cord injury (SCI). Bruton tyrosine kinase (BTK) activation
mechanistically links these neuroimmune mechanisms. Our objective is to use Ibrutinib, an FDAapproved BTK inhibitor, to inhibit the neuroimmune cascade thereby improving locomotor recovery
after SCI. Rat models of contusive SCI, Western blot, immunofluorescence staining imaging, flow
cytometry analysis, histological staining, and behavioral assessment were used to evaluate BTK
activity, neuroimmune cascades, and functional outcomes. Both BTK expression and phosphorylation
were increased at the lesion site at 2, 7, 14, and 28 days after SCI. Ibrutinib treatment (6 mg/kg/day,
IP, starting 3 h post-injury for 7 or 14 days) reduced BTK activation and total BTK levels, attenuated
the injury-induced elevations in Iba1, GFAP, CD138, and IgG at 7 or 14 days post-injury without
reduction in CD45RA B cells, improved locomotor function (BBB scores), and resulted in a significant
reduction in lesion volume and significant improvement in tissue-sparing 11 weeks post-injury. These
results indicate that Ibrutinib exhibits neuroprotective effects by blocking excessive neuroimmune
responses through BTK-mediated microglia/astroglial activation and B cell/antibody response in rat
models of SCI. These data identify BTK as a potential therapeutic target for SCI.
Keywords: Bruton tyrosine kinase; Ibrutinib; neuroimmune; spinal cord injury; locomotion; neuroprotection; B cells; glial cells
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1. Introduction
Traumatic spinal cord injury (SCI) impacts motor, bowel, bladder, and sexual function,
resulting in a tremendous socioeconomic impact on affected individuals and the health
care system [1,2]. In the United States, there are over 17,000 new injuries each year [3],
with approximately 300,000 persons living with an SCI [4], based on SCI incidence and
prevalence and extrapolating from the 2020 census. Current treatments for acute SCI are
largely limited to stabilizing the spine and providing palliative care. No approved therapies
are available for reducing motor impairment, bladder dysfunction, and other deficits.
Over the past two decades, it has become evident that SCI elicits multicellular and
sequential acute inflammatory and delayed autoimmune responses which include activation of microglia, macrophages, and astrocytes, along with B lymphocytes [5–11]. B cells
play a central role in the adaptive immune system and autoimmunity, while microglia,
macrophages, and astrocytes are key mediators of the innate immune system and inflammatory response. Although the inflammatory and immune systems can be neuroprotective
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and growth promoting, their excessive activation shifts the pendulum towards pathology
and contributes to neurodegeneration and resultant functional deficits following SCI.
The inflammatory response within the first few days post-injury consists of activation of pro-inflammatory M1-microglia, macrophages, and astrocytes that trigger activation of NLRP3 inflammasomes and production of oxidative enzymes (NOX2) and
pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-18,) [6,12–22]. Contusive SCI also activates B cells over days to months. Autoreactive B cell activation contributes to plasma cell
formation to produce autoantibodies, causing axon/myelin damage [23–31]. The autoimmune and inflammatory cascades exacerbate spinal tissue/axon damage, locomotor deficits
and bladder dysfunction [12,16,17,24,32–36]. As the inflammatory/immune cascades have
both pathogenic and protective roles after SCI, a challenge is to reduce the pathogenic
autoimmune and pro-inflammatory cascades and promote functional recovery following
SCI without creating immunodeficiency.
Evidence is accumulating that Bruton’s tyrosine kinase (BTK) is a key regulator of
the innate and adaptive immune systems. However, this is largely based on findings in
non-CNS injury and autoimmune disorders such as lupus, rheumatoid arthritis, and B cell
malignancies [37–40].
BTK was originally identified as the gene mutated in X-linked agammaglobulinemia
(XLA) and was subsequently shown to be the rate-limiting step in B cell receptor signaling
and B cell survival and differentiation [41,42]. BTK links B cell receptor activation to B
cell survival through phosphorylation (activation) of BTK at Y551 by Src family kinases
including Syk (spleen tyrosine kinase) and autophosphorylation at Y223 [43]. Phospho-BTK
activates NF-κB pathways, leading to gene transcription, B cell proliferation and differentiation into plasma cells. Thus, BTK is an important mediator of the B cell component of the
adaptive immune response [44]. BTK is also present in myeloid cells including microglia,
macrophages, and neutrophils—components of the innate immune/inflammatory response
in the CNS [45,46]. BTK inhibition reduces the inflammatory response in a range of conditions including pneumonia, arthritis, ischemic brain injury, and lipopolysaccharide-induced
inflammation [47–52].
The objective of this study was to evaluate the neuroprotective effects of BTK inhibition
against the pathogenic neuroimmune injury cascades, tissue damage, and locomotor deficits
following SCI. The BTK inhibitor used, Ibrutinib (Imbruvica® , previously PCI-32765), is a
first-in-class irreversible inhibitor of BTK and is FDA approved for chronic lymphocytic
leukemia [53]. Ibrutinib forms a covalent bond with Cys-481 in the ATP binding site of BTK
(Cys-483 in rat BTK).
2. Results
No significant differences in actual force, displacement, or velocity were found between Ibrutinib-treated and vehicle-treated groups, indicating similar injuries to all animals
(Table 1). Ibrutinib treatment was well tolerated and did not result in alterations in body
weight, as compared to vehicle-treated animals, following SCI (Table 2). Bladder infection,
detected by examining urine color (green-yellow) and transparency (cloudy) and hematuria,
were not observed in any of the rats. Similarly, we did not observe bleeding in the eyes,
forelimbs, and hindlimbs.
Table 1. Injury Parameters. Values are mean ± SEM. No significant differences in impact force,
displacement, and velocity were found between the Ibrutinib treatment and vehicle groups (n = 10
per group).
Treatment Group

Actual Force
(kdyn)

Displacement
(µm)

Velocity
(mm/s)

SCI + Ibrutinib

183.00 ± 0.95

1095.00 ± 54.6

123.10 ± 1.69

SCI + Vehicle

184.20 ± 0.96

1241.30 ± 88.19

121.60 ± 1.43

Treatment Group

(kdyn)
183.00 ± 0.95
184.20 ± 0.96

SCI + Ibrutinib
SCI + Vehicle
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Groups
Ibr *
Veh

1W
266 ± 2.9
259 ± 5.3

Groups

1W

Ibr *
Veh

(μm)
1095.00 ± 54.6
1241.30 ± 88.19

(mm/s)
123.10 ± 1.69
121.60 ± 1.43
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Table 2. Body Weight of Animals Per Week (G). Values are Mean ± SEM. At 1, 2, 3, 4 and 11 weeks,
there are no significant differences in the bodyweight of animals per week were found between the
vehicle- and Ibrutinib-treated animals (n = 10 per group); At 5, 6, and 7 weeks Ibrutinib treatment
increased
bodyWeight
weightofofAnimals
animals Per
per Week
week compared
vehicle-treated
* Ibr:
Ibrutinib
Table
2. Body
(G). Valuestoare
Mean ± SEM.group.
At 1, 2,
3, 4SCI
and+11
weeks,
treatment;
Veh:
SCI
+
Vehicle
treatment.
there are no significant differences in the bodyweight of animals per week were found between the

Ibrutinib-treated
(n = 10 per 6W
group); At 5, 7W
6, and 7 weeks
Ibrutinib treatment
2Wvehicle- and3W
4W animals
5W
8W
11W
increased
body
weight
of
animals
per
week
compared
to
vehicle-treated
group.
*
+ Ibrutinib
266 ± 2.8
272.3 ± 2.5 278 ± 2.3 290 ± 1.8 * 301 ± 3.1 * 312 ± 4.8 * 321 ±Ibr:
6.1SCI 340
± 9.9
treatment; Veh: SCI + Vehicle treatment.
261 ± 6.9
263.3 ± 5.6 268 ± 5.2 276 ± 4.8
286 ± 5.5
294 ± 6.6
305 ± 6.9
317 ± 9.8
2W

3W

4W

5W

6W

7W

8W

11 W

266 ± 2.9

2.1. BTK Upregulation and Phosphorylation (Activation) following SCI, and Inhibition by
266 ± 2.8
272.3 ± 2.5
278 ± 2.3
290 ± 1.8 * 301 ± 3.1 * 312 ± 4.8 *
321 ± 6.1
340 ± 9.9
Ibrutinib

259 ± 5.3

261 ± 6.9

263.3 ± 5.6

268 ± 5.2

276 ± 4.8

286 ± 5.5

294 ± 6.6

305 ± 6.9

317 ± 9.8

Following contusive SCI (180 kdyn, T10) produced using the Infinite Horizons (IH)
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Figure 1.
treatment
onon
BTK
phosphorylation
andand
total
BTKBTK
protein
anFigure
1. Effects
EffectsofofSCI
SCIand
andIbrutinib
Ibrutinib
treatment
BTK
phosphorylation
total
protein
alyzed
by
quantification
of
Western
blotting
data.
Western
blot
analysis
of
spinal
cord
samples
(60
analyzed by quantification of Western blotting data. Western blot analysis of spinal cord samples
µg of protein extract each sample) at lesion epicenter showed that contusion injury increased BTK
(60 µg of protein extract each sample) at lesion epicenter showed that contusion injury increased BTK
phosphorylation and total BTK protein in the spinal cord 2 (A), 7 (B), and 14 (C) days post-injury
phosphorylation and total BTK protein in the spinal cord 2 (A), 7 (B), and 14 (C) days post-injury
compared with sham-operated animals. Ibrutinib treatment 6 mg/kg/day, Scheme 3 h post-injury
for 7 and 14 days resulted in reduced levels of BTK phosphorylation and total BTK protein in the
spinal cord lesion site at 7 (B) and 14 (C) days after contusive SCI compared with vehicle-treated
animals. Quantification of total BTK/GADPH or phospho-BTK/GAPDH (%Sham control for 2-day
time point and %Sham + Vehicle for 7 and 14 days- time points) after contusive SCI was performed
by the fold of blot density (GAPDH as loading control). Antibodies were specific for the total BTK or
BTK phosphorylation (phospho-BTK-Y223). Data are presented as mean ± S.E.M. (for 7-day time
point, n = 4 per group, for 14-day time point, n = 2 per group) and analyzed with one-way ANOVA
followed by Bonferroni post hoc analysis, (B,C): * p < 0.05, *** p < 0.001 compared to vehicle-treated
SCI animals. (A): * p < 0.05, *** p < 0.001, compared to sham control, t-test, n = 3 per group.
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compared with sham-operated animals. Ibrutinib treatment 6 mg/kg/day, Scheme 3 h post-injury
for 7 and 14 days resulted in reduced levels of BTK phosphorylation and total BTK protein in the
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animals. Quantification of total BTK/GADPH or phospho-BTK/GAPDH (%Sham control for 2-day
time point and %Sham + Vehicle for 7 and 14 days- time points) after contusive SCI was performed
by the fold of blot density (GAPDH as loading control). Antibodies were specific for the total BTK
or BTK
phosphorylation
(phospho-BTK-Y223).
Data
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mean
(for 7-day time
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(6 mg/kg/day,
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for 7asand
14 ±S.E.M.
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point, n = 4 perelevation
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analyzed
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(Figure
2D)
post-SCI.
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the elevations
in IgGinatIgG
bothatpost-injury
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tinib treatment
prevented
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Figure 2.
2. Effects
Effectsof
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Ibrutinibpost-treatment
post-treatmenton
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levelsofofCD138
CD138and
andtotal
totalIgG.
IgG.
analyzed
quantifiFigure
analyzed
byby
quantificacation
of
Western
blotting
data.
Western
blot
analysis
of
spinal
cord
samples
(60
µg
of
protein
extion of Western blotting data. Western blot analysis of spinal cord samples (60 µg of protein extract
tract each sample) at lesion epicenter showed that contusion injury increased CD138 (A,B) and total
each sample) at lesion epicenter showed that contusion injury increased CD138 (A,B) and total IgG
IgG (C,D) in the spinal cord 7 (A,C) and 14 (B,D) days post-injury compared with sham-operated
(C,D) in the spinal cord 7 (A,C) and 14 (B,D) days post-injury compared with sham-operated animals.
animals. Ibrutinib treatment (6 mg/kg/day, starting at 3h post-injury for 7 days) resulted in reduced
Ibrutinib
treatment
(6 mg/kg/day,
3 hspinal
post-injury
for 7 days)
in reduced
levels of CD138
(A,B)
and total IgGstarting
(C,D) inatthe
cord lesion
site atresulted
7 (A,C) and
14 (B,D)levels
days
of
CD138
(A,B) and
total IgG (C,D)
the spinal cord
lesion Quantification
site at 7 (A,C) and
14 (B,D) days after
after
contusive
SCI compared
with in
vehicle-treated
animals.
of CD138/GADPH
and
contusive
SCI compared
with
vehicle-treated
animals.
Quantification
CD138/GADPH
and total
total IgG/GAPDH
7 and 14
days
after contusive
SCI was
performed byofthe
fold of blot density.
Data
IgG/GAPDH 7 and 14 days after contusive SCI was performed by the fold of blot density. Data are
presented as mean ± S.E.M., n = 4 per group (7-day time point) or n = 2 per group (14-day time point),
and analyzed with one-way ANOVA followed by Bonferroni post hoc analysis, * p < 0.05, ** p < 0.01,
*** p < 0.001, compared to vehicle-treated SCI animals.
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are presented as mean ±S.E.M., n = 4 per group (7-day time point) or n = 2 per group (14-day time
5 of 18
point), and analyzed with one-way ANOVA followed by Bonferroni post hoc analysis, * p < 0.05, **
p < 0.01, *** p < 0.001, compared to vehicle-treated SCI animals.

2.3. Ibrutinib Did Not Result in Reduced Levels of Splenic B Cells
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B cells.

Figure 3. Ibrutinib did not reduce CD45RA-positive B cell population after SCI
SCI Injury.
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SCI resulted in a dramatic 7-fold elevation in Iba1 levels at seven days post-injury
(Figure 5). This increase was reduced, but not abolished, following treatment with Ibrutinib.
SCI resulted in a modest elevation in GFAP levels at the 7-day time point, which was
prevented by Ibrutinib treatment.
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Figure 4. Phospho-BTK is localized to microglia 3 days following SCI, measured by immunofluorescence imaging. Photomicrographs of representative transverse spinal sections taken from spinal
cord injured rat. Double immunofluorescent imaging analysis of spinal cord sections at lesion site
showed phospho-BTK (red) expressed in microglia (Iba1, green) 3 days post-injury. The sections
were immunostained with a primary antibody against phospho-BTK (red), and Iba1 (green) and
counterstained with DAPI to identify cell nuclei. Phospho-BTK immunostaining was uniformly observed
in
cells
immunoreactive
fortoto
Iba1
(a specific
calcium-binding
protein for
of microFigure4.
4.Phospho-BTK
Phospho-BTK
localized
microglia
days
followingSCI,
SCI,measured
measured
byactivation
immunofluoFigure
isislocalized
microglia
33days
following
by
immunofluoglia
and
macrophages
[54]).
This
is
from
3
days
post
SCI,
at
which
time
the
Iba1
cells
are
predomirescence
imaging.
Photomicrographs
of
representative
transverse
spinal
sections
taken
from
spinal
rescence imaging. Photomicrographs of representative transverse spinal sections taken from spinal
cord injured
rat. Double
immunofluorescent
analysis
of spinal
cordThe
sections
at lesion
nantly
microglia.
The SCI
conditions are asimaging
described
in other
figures.
images
were site
obtained
cord injured rat. Double immunofluorescent imaging analysis of spinal cord sections at lesion site
showed
expressed
in microglia
3 days
post-injury.
sections
from
the phospho-BTK
ventral white (red)
matter,
in a section
rostral (Iba1,
1 mmgreen)
from the
lesion
epicenterThe
using
the Nikon
showed phospho-BTK (red) expressed in microglia (Iba1, green) 3 days post-injury. The sections
were immunostained
with a primary
antibody
againstNY,
phospho-BTK
(red),
andCord
Iba1 (green)
andInjury
confocal
microscopy system
(Nikon C2+,
Melville,
USA) in the
Spinal
and Brain
were
immunostained
with atoprimary
antibody
phospho-BTK (red), and was
Iba1 (green) and
counterstained
DAPI
identify
nuclei.against
Phospho-BTK
Research
Centerwith
imaging
core
at thecell
University
of Kentucky.immunostaining
Scale bar: 10 µm. uniformly ob-

counterstained
DAPI to identify
cell (a
nuclei.
Phospho-BTK
immunostaining
was uniformly
observed in cellswith
immunoreactive
for Iba1
specific
calcium-binding
protein for activation
of microserved
in cells
immunoreactive
for Iba1
(a specific
protein
for activation
of microglia
glia and
macrophages
[54]). This
is from
3 days calcium-binding
post SCI, at which
time the
Iba1 cells are
predomiSCI
resulted
inThis
a dramatic
7-fold
elevation
in Iba1
levels
atimages
seven
days post-injury
and
macrophages
is from 3 days
post
SCI, at which
time
the Iba1
cells
are predominantly
nantly
microglia.[54]).
The SCI
conditions
are as
described
in other
figures.
The
were obtained
(Figure
5).
This
increase
was
reduced,
but
not
abolished,
following
treatment
with
from the ventral
matter,
section rostral
1 mm
from The
the lesion
using the
Nikon
microglia.
The SCIwhite
conditions
areinasa described
in other
figures.
imagesepicenter
were obtained
from
the Ibrutinib.
confocal
microscopy
system
(Nikon
C2+,
Melville,
USA) epicenter
in the Spinal
Cord
Brain
Injury
ventral
white
matter, in
a section
rostral
1 mm
from NY,
the lesion
using
the and
Nikon
confocal
Research
Center
imaging
core
at
the
University
of
Kentucky.
Scale
bar:
10
µm.
SCI
resulted
in
a
modest
elevation
in
GFAP
levels
at
the
7-day
time
point,
which
microscopy system (Nikon C2+, Melville, NY, USA) in the Spinal Cord and Brain Injury Research was
prevented
by core
Ibrutinib
treatment.
Center imaging
at the University
of Kentucky. Scale bar: 10 µm.

SCI resulted in a dramatic 7-fold elevation in Iba1 levels at seven days post-injury
(Figure 5). This increase was reduced, but not abolished, following treatment with Ibrutinib.
SCI resulted in a modest elevation in GFAP levels at the 7-day time point, which was
prevented by Ibrutinib treatment.
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±S.E.M., n = 4 per group, and analyzed with one-way ANOVA followed by Bonferroni post hoc
analysis, * p < 0.05, ** p < 0.01compared to vehicle treated SCI animals.
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Figure 8. Effects of the 2‒week treatment with Ibrutinib on lesion epicenter and spread of tissue
damage after Scheme 2. Two‒week treatment with Ibrutinib resulted in significant increases in

Figure
ofthe
the2-week
2‒week
treatment
with
Ibrutinib
on lesion
epicenter
and spread
tissue
Figure 8. Effects
Effects of
treatment
with
Ibrutinib
on lesion
epicenter
and spread
of tissueofdamage
damage after Scheme 2. Two‒week treatment with Ibrutinib resulted in significant increases in

Int. J. Mol. Sci. 2022, 23, 355

9 of 18

after Scheme 2. Two-week treatment with Ibrutinib resulted in significant increases in tissue-sparing
at the epicenter, 1, 2, & 3 mm rostral to the injury epicenter, and 1 mm caudal to the lesion epicenter
(A), white matter sparing at lesion epicenter and 1 mm caudal to the lesion epicenter (B), and gray
matter sparing at epicenter, 2 mm, 1 mm rostral and 1 mm caudal to the lesion epicenter (C) at
11 weeks following contusion injury to the spinal cord (T10, 180 kdyn). Data were presented as mean
± SEM and analyzed with repeated measures ANOVA followed by Bonferroni post-hoc analysis,
* p < 0.05, ** p < 0.01, and *** p < 0.001, compared with vehicle treatment, n = 5/group. Bottom
Panel: Photomicrographs of representative transverse spinal cord sections from rats at 11 weeks after
contusive SCI (T10, 180 kdyn). The sections were from the lesion epicenter, obtained from a Sham
(left), vehicle-treated injured rat (middle), and Ibrutinib (6 mg/kg/day)-treated injured rat (right).
The sections were stained with eriochrome cyanine for myelin. Scale bar: 100 µm.

3. Discussion
The goals of the present study were to (1) determine if BTK expression was altered
and if BTK was activated following SCI; (2) to evaluate whether BTK inhibition would
reduce B cell autoimmune and inflammatory responses following SCI; and (3) to examine if
BTK inhibition would result in improved pathological and functional outcomes. This was
evaluated using a rat T10 contusion injury model of moderate-severe spinal cord injury.
The results demonstrate BTK activation (phosphorylation) and BTK protein upregulation at 2-, 7- and 14-days following SCI. Previously, we observed elevated BTK expression
and BTK phosphorylation in SCI-injured rats at four weeks post-injury [17]. BTK was
originally identified as the gene mutated in X-linked agammaglobulinemia (XLA) and was
subsequently shown to be the rate-limiting step in B cell receptor signaling and autoreactive
B cell survival and differentiation [41,42]. BTK is an important mediator of the autoreactive
B cell component of the autoimmune response [44]. Thus, the upregulation and activation
of BTK following SCI are hypothesized to contribute to pathogenic B cell activation and
autoimmunity observed following SCI.
Following low thoracic SCI in mice, B cells proliferate in bone marrow and spleen and
then migrate to the injury site [9]. B cells are activated to form antibody-secreting plasma
cells. At the injury site, B cells form structures similar to ectopic follicles and produce
autoreactive immunoglobulins [9,24]. Antibody secreting B cells are found in the injured
spinal cord and CSF, and antibodies isolated from injured mice cause pathology in naïve
mice [24]. Autoantibodies and autoimmunity are also evident following human SCI [58–60].
We therefore sought to determine if BTK inhibition would alter levels of B cells, plasma
cells, and immunoglobulins following SCI.
Administration of Ibrutinib following SCI abolished the SCI-induced elevation of BTK
and pBTK. Ibrutinib treatment also decreased levels of CD138, a marker of plasma cells [61],
and reduced IgG levels following SCI. SCI did not increase, and Ibrutinib treatment did not
reduce, numbers of splenic B cells at seven days post-injury. The effects of Ibrutinib on B
cell activation (pBTK), plasma B cell (CD138), and IgG levels in the injured spinal cord are
consistent with elevated BTK levels and activation following SCI promoting pathogenic B
cell activation and autoimmunity [62]. However, the lack of change in splenic B cell levels
following both SCI and Ibrutinib treatment was surprising.
Splenic CD45R+ B cell levels are significantly elevated within seven days of a moderate
severity contusive SCI at thoracic level T9 in mice, with levels peaking at 14 days and
remaining elevated through 28 days post-SCI [9]. Following moderate severity contusive
SCI in rats at T10, we previously observed a modest but significant increase in CD45RA+
B cells at 28 days post-injury [17]. The lack of significant increase in splenic CD45RA+ B
cells at 7 days following SCI in the present study may reflect differences in the robustness
of the B cell response to injury in mice vs. rats, the relatively early post-injury time point
examined, or a combination of the above. In contrast to low thoracic injury, splenic B
cell levels are decreased following clip-compression SCI in rats at C7-T1 and following
higher thoracic injury (T3) in mice due to disruption of the sympathetic nervous system
and resultant immunosuppression [63,64].
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Ibrutinib treatment decreased levels of plasma cell marker CD138 and IgG in the
injured spinal cord but did not alter splenic B cell numbers. Enhanced BTK activity is
implicated in the breach of self-tolerance checkpoints in autoimmunity [65]. Overexpression
of BTK in B cells results in germinal center and plasma cell formation, antinuclear antibody
production, and autoimmune disorders [39,65–67]. Importantly, BTK appears to act as
a rheostat and not as an on-off switch, with overexpression leading to autoimmunity
while BTK inhibition improves outcomes of autoimmune disorders such as rheumatoid
arthritis and multiple sclerosis [40,48,68]. In a BTKlo lyn−/− mouse model, mice with
reduced levels of BTK expression did not develop autoantibodies but had normal B cell
development [69]. Autoreactive B cells depend upon BTK for survival to a greater degree
than normal B cells and BTK inhibition suppresses autoreactive B cell differentiation into
plasma cells and autoantibody production without creating B cell immunodeficiency [40].
The reduction in CD138 and IgG immunoreactivity in the injured spinal cord following
Ibrutinib treatment is consistent with BTK acting as a rheostat in B cell activation and
development and demonstrates that BTK inhibition may prevent the over-activation of
B cells and the autoimmune response following SCI, while preserving normal levels of B
cells. This contrasts with B cell-depletion via anti-CD20 antibodies, which suppresses both
pathogenic and normal B cells after SCI [24,70,71], resulting in increased vulnerability to
opportunistic infection due to immunodeficiency [28,72].
In addition to B cells, BTK is expressed in B cells and in cells of myeloid origin
including macrophages, microglia, and neutrophils, components of the CNS innate immune system [47]. Originally thought to be non-functional due to the lack of B cell receptors in myeloid cells, BTK was subsequently shown to regulate activation of monocytes,
macrophages, and microglia, with BTK deficiency resulting in reduced inflammatory responses [49,73,74]. Daily Ibrutinib treatment following SCI significantly attenuated the
SCI-induced elevation in the microglia/macrophage marker Iba1 at the lesion site on
the spinal cord seven days post-SCI, consistent with reduced microglial activation and
macrophage infiltration. Ibrutinib also reduced the recruitment of neutrophils to the injured spinal cord at 24 h post-injury, following administration immediately after or 12 h
post-injury, or both [75].
BTK deficient mice, and mice treated with Ibrutinib, exhibit decreased recruitment of
M1 macrophages/microglia following intraperitoneal administration of lipopolysaccharide
and also show increased expression of immunosuppressive M2-associated markers following M1 polarizing stimuli [52,76]. BTK blockade also reduces microglial phagocytosis
in vitro and in vivo [74]. Together, these results demonstrate that post-injury administration of Ibrutinib attenuates the myeloid-cell mediated inflammatory response following
SCI, reducing the activation of microglia and the infiltration of macrophages. BTK inhibition may also alter the phenotype of microglia and macrophages following SCI based on
findings in other models of inflammation.
Although not myeloid cells, reactive astrocytes are increasingly recognized as a component of the innate immune response to CNS injury and of the adaptive immune response and autoimmunity [77–81]. In the initial stages, reactive astrocytes surround the
lesion site and protect against the spread of injury. Later, hypertrophic astrocytes express
pro-inflammatory factors and chondroitin sulfate proteoglycans (CSPGs), contributing to
neurodegeneration and glial scar formation [17,82]. The present data demonstrated that
Ibrutinib treatment reduced levels of the astrocytic marker glial fibrillary acidic protein
at seven days following SCI. This is likely an indirect effect of Ibrutinib on microglia and
macrophages, as activated microglia can induce astrocytes to become reactive and neurotoxic [20]. Previously, Ibrutinib administration in mice reduced both microglial and
astrocyte activation following intraperitoneal injection of LPS in mice [52].
Based on the results of the present study showing that BTK signaling is critical to
both B cell autoimmune and microglia/macrophage and astrocyte inflammatory responses
after SCI, the third objective of the present study was to investigate whether post-injury
administration of the BTK inhibitor Ibrutinib would reduce pathological and functional
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deficits after SCI in rats. Ibrutinib, administered IP at 6 mg/kg/day, beginning 3 h following
contusive SCI followed by daily administration for two weeks, resulted in improved
recovery of locomotor function and increased total tissue sparing, white matter sparing
and gray matter sparing.
Ibrutinib (Imbruvica® , previously PCI-32765), is a first-in-class irreversible inhibitor
of BTK, forming a covalent bond with Cys-481 in the ATP binding site (Cys-483 in rat
BTK). It is the most studied BTK inhibitor and is FDA approved for chronic lymphocytic
leukemia [53]. Major adverse events include low platelet count, rash, diarrhea, and bruising
(prescribing information for Ibruvica). It was also reported that there is an increased risk
of bleeding and opportunistic infections. The latter two are of particular relevance to
SCI. Bleeding is usually mild, rarely causes discontinuation of treatment, and results
from multiple mechanisms including pre-treatment platelet levels [83,84]. With regard to
infections, mechanisms implicated include thrombocyte impairment by Ibrutinib, but not
other BTK inhibitors; off-target impairment of the ITK kinase expressed in T cells; and also
impaired activation and M1 polarization of macrophages [53,85].
The off-target effects of Ibrutinib led to the development of second-generation BTK
inhibitors with improved specificity [53,86]. We chose Tolebrutinib (SAR442168; PRN2246)
for the proposed future studies. Tolebrutinib has improved penetration of the bloodbrain barrier as compared to Ibrutinib, a greater affinity for BTK, and is in phase III
clinical trials for primary progressive and relapsing multiple sclerosis [87,88] (Clinical trials
NCT04410978; N CT04458051. Although Tolebrutinib has improved specificity for BTK as
compared to Ibrutinib, it also inhibits TEC kinase, which also has Cys at a similar position
in the ATP binding site, as do all irreversible BTK inhibitors [83]. Tolebrutinib did not result
in bleeding in phase I trials [83,89].
In conclusion, the present study demonstrates that: (1) BTK activation and total BTK
upregulation are implicated in neuroimmune pathogenesis of traumatic SCI and represent
a promising therapeutic target; (2) BTK inhibition with Ibrutinib attenuates plasma cell
formation and antibody production as well as activation of pro-inflammatory microglia,
macrophages and astrocytes without causing a reduction of normal B cells; and (3) BTK
inhibition with Ibrutinib treatment exhibits neuroprotective effects against tissue damage
and locomotor deficits in rat models of SCI. Together, these results suggest the Bruton’s
tyrosine kinase inhibitors as potential therapeutic agents for SCI.
4. Materials and Methods
4.1. Rigorous Experimental Design
Rats were randomly assigned to each group using Research Randomizer. All personnel
who perform assessments were blinded to the treatment assignment. The sample size was
determined, based on previous studies and power analysis to ensure sufficient statistical
power.
4.2. Animals
Female Sprague–Dawley (SD) rats approximately three months of age, weighing
200–250 g, were used (Charles River, Indianapolis, IN, USA). Female rats are used due to
the need for manual post-injury bladder expression, which is facilitated in females due to
their shorter urethra. Given the neuroprotective effects of estrogen and progesterone and
sex differences in many acute injury paradigms, it is essential to confirm efficacy in male rats
in future studies. Rats were kept under standard housing conditions for at least one week
following arrival in an enclosed, pathogen-free animal facility. All experimental procedures
were approved and carried out in accordance with the Guidelines of the US National
Institutes of Health and the Institutional Animal Care and Use Committee (IACUC) of the
University of Kentucky.
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4.3. Antibodies and Chemicals
Ibrutinib was purchased from MedChemExpress LLC (Monmouth Junction, NJ, USA).
Anti-IgG and anti-Syndecan-1 (CD138, ab60199) antibodies were purchased from Abcam
(Cambridge, MA, USA). Anti-phospho-BTK-Y223 antibody (5082), Total BTK (D3H3) antibody (5847), and anti-GFAP (D1F4Q)XP (12389) antibody were purchased from Cell Signal
Technology. PE mouse anti-rat CD45RA antibody was purchased from BD Bioscience.
Anti-GAPDH antibody and Iba1 antibody (SAB2702364) for Western blot were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Anti-Iba1 monoclonal antibody (MA5-27726),
phosphor-BTK (Tyr223) polyclonal antibody (PA5-105619), goat-anti mouse Alexa Fluor
488 antibody (A-31620) and Donkey anti-rabbit Alexa Fluor 594 antibody were purchased
from Fisher Thermo Scientific. Goat anti-mouse IR Dye 680 antibody, goat anti-rabbit
IR Dye 680 antibody, goat anti-mouse IR Dye 800 antibody, and goat anti-rabbit IR Dye
800 antibody were purchased from Li-Cor.
4.4. Contusional SCI
SCI was modeled in rats using a moderately severe contusion injury (180 kdyn, T10,
Infinite Horizon SCI Impactor) [17]. The contusive rat thoracic SCI is widely used and
produces similar morphological, biochemical, and functional outcomes as compared to
humans following SCI [17,90]. The moderately severe contusion injury (force setting
180 kdyn) results in partial deficits in hindlimb function in rats [91].
4.5. Ibrutinib Intraperitoneal (IP) Administration
Ibrutinib solutions were made by adding each solvent one by one in 5% DMSO, 40%
PEG300, 5% Tween 80, and 50% saline, based on manufacturer recommendations for in vivo
studies. Rats were randomly assigned to the following groups: (1) Sham operation without
injury; (2) SCI; (3) SCI-injured rats received daily I.P. injections of 6 mg/kg/day of Ibrutinib
for 1 week, beginning 3 h postinjury; (4) SCI-injured rats received daily I.P. injections of
vehicle (5% DMSO, 40% PEG300, 5% Tween 80, and 50% saline) for 1 week, beginning 3 h
postinjury; (5) SCI-injured rats received daily I.P. injections of 6 mg/kg/day of Ibrutinib
for 2 weeks, beginning 3 h postinjury; (6) SCI-injured rats received daily I.P. injections of
vehicle for 2 weeks, beginning 3 h postinjury.
The Ibrutinib dosage is based on the dose used for chronic lymphocytic leukemia
(therapeutic dose range 10–40 mg/kg/day for rats compared to 420 to 560 mg once daily
for humans).
Lowering the Ibrutinib dose (6 mg/kg/day for rats) in this study was used to reduce
the risk of side effects (bleeding). Lowering the dose of ibrutinib has clear potential to
reduce the bleeding side effects of ibrutinib [92].
The starting time of intervention, beginning at 3 h post-injury, was chosen based on our
recent study [17]. The therapeutic window will be further evaluated in future studies. The
1-week Ibrutinib treatment duration was chosen to target the acute microglia/macrophage
activation after contusive SCI in rats [6], while the 2-week Ibrutinib treatment duration
was designed to target the time course of the proliferation of astrocytes and B cells after
contusive SCI in rats [17]. In mice, B cell proliferation peaks at 14 days and remains elevated
at 28 days following contusive SCI [24].
4.6. Assessment of Locomotor Function
Open-field locomotor function was evaluated pre-injury, immediate, 3, and 7 days
post-injury, and then weekly from until 4 or 11 weeks post-injury using the Basso, Beattie,
and Bresnahan (BBB) rating scale [93] as in our previous studies [17,94]. Two evaluators,
trained and certified by the Ohio State program, participated in the assessment in a blinded
manner.
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4.7. Monitoring Bladder Infection and Bleeding
Bladder infections were measured by examining urine color (green-yellow) and Transparency (cloudy). Rats were treated prophylactically with Cefazolin for the one week
following injury to minimize the risk of bladder and other infections. Animals were
checked twice a day for first 3 weeks, then twice a week, including body weight, bladder
infection, bleeding, general activity, and breaths. Presence and extent of blood in urine
were recorded. Bleeding was also evaluated by examining the hemorrhage at the lesion
site, and by inspecting for bleeding/bruises in the eyes, forelimbs, and hindlimbs.
4.8. Spinal Cord Tissue Processing
For Western blot analysis, animals were euthanatized at 2, 7, or 14 days post-injury
by Fatal Plus containing pentobarbital (100 mg/kg for rats, I.P. injection, n = 4 per group).
A 5-mm spinal cord centered on the lesion site was removed and snap-frozen on dry ice,
then stored at −80 ◦ C. For histological staining analysis, at the conclusion of the locomotor
assessment, animals were anesthetized and transcardially perfused with cold 0.1 M PBS,
followed by 4% paraformaldehyde in phosphate-buffered saline (n = 5 per group). The
spinal cords were removed and post-fixed with the same fixative overnight. Fixed spinal
cord blocks (2 cm in length) centered at the lesion epicenter were immediately dissected,
post-fixed in the same fixative solution for 4 h at 4 ◦ C, cryoprotected in 30% sucrose in
phosphate-buffered saline at 4 ◦ C. Spinal cords were serially cryosectioned at a thickness of
20 µm. Every fifth section (interval between 100 µm) was mounted onto each Fisherbrand
Superfrost Plus slide. The interval between two sections on each slide is 1 mm. Ten sets of
slides were collected and stored at −20 ◦ C.
4.9. Assessment of Lesion Volume, Total Tissue Sparing, White Matter Sparing, and Gray
Matter Sparing
A modified histological eriochrome cyanine (EC) staining plus cresyl violet staining
protocol for myelin that differentiates both white matter and cell bodies was performed to
visualize spared spinal tissue in one set of slides, as described in our previous study [17].
Image analysis was performed on each EC-stained section and histological outcomes were
evaluated by measuring total spinal section area, gray matter sparing, and lesion area
on individual sections using Helo Axio Image System. Total tissue sparing, white matter
sparing, gray matter sparing and lesion volume were analyzed from 11 evenly spaced
sections as described in our recent study [17].
4.10. Western Blotting
Spinal cord protein samples were processed and analyzed using Western blotting as
described in our previous study [17]. Briefly, the protein samples (60 µg of protein extract
each sample) were loaded on SDS-PAGE gels and electrotransferred to nitrocellulose
membranes. After transfer, membranes were incubated in blocking buffer (5% powdered
milk in 1× TBS, 0.1% Tween 20) for 1 h at room temperature and incubated at 4 ◦ C
overnight with one of the primary antibodies. Blots were probed with a primary antibody
against specific targets and reprobed with a secondary antibody against GADPH as a
loading control. Blots were then incubated with IRDye anti-rabbit or anti-mouse secondary
antibodies (1:5000). Blots were visualized and analyzed on the Li-Cor Odyssey infrared
imaging system (Lincoln, NE, USA).
4.11. Double Immunofluorescence Confocal Imaging Analysis
Double immunofluorescence staining was performed as previously described [36].
Briefly, spinal cord cross-sections at the lesion site were incubated with an anti-mouse monoclonal antibody against Iba1 (GT10312, MA5-27726), 1:100; microglia/macrophage marker)
or GFAP (GA5 mouse mAb #3670, CST) and a polyclonal antibody against phosphor-BTK
(Tyr223, Tyr225) followed by incubation with Alexa Fluor 488 or 594-conjugated goat-anti
rat secondary antibody. Using a laser scanning confocal microscopy system (Nikon C2+,
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Melville, NY, USA), the fluorescent Ibal/pBTK co-localization signals within the spinal
cord section in the lesion site were captured (magnification 100×).
4.12. Flow Cytometry Analysis
Sham-operated and injured rats with the treatment of Ibrutinib or vehicle were euthanized at 1-week post-injury or sham operation. Spleen samples were collected and
processed for measuring the population of splenic CD45RA+ B cells using PE mouse antirat CD45RA antibody (Cat# 551402, BD Bioscience) and flow cytometry. Immediately after
deep anesthesia, the spleen samples were collected. The spleen samples were removed
and minced in a 3.5 cm-dish with Hank’s Balanced Salt Solution (HBSS, Invitrogen), then
transferred to a 50 mL-tube with HBSS. The splenic cell samples were then passed through
40-µm nylon cell strainer to obtain a single-cell suspension as previously described [17].
Red blood cells (RBCs) in the resulting splenic cells were lysed using RBC lysis buffer
(eBioscience). After washing, the splenic cell samples were resuspended in 5 mL of RPMI
1640 (Invitrogen). Flow cytometry system (Sony SY3200, Cell Sorter, Sony Biotechnology
iCyT, San Jose, CA, USA, using the Core Facility) was used to measure the populations
of CD45RA+ B cells in the splenic cell samples using antibodies against CD45RA (BD
Bioscience) according to the manufacturer’s instructions and our recent study [17]. The
population of CD45RA-positive B cells was automatically calculated as the percentage of
specific CD45RA-positive cells.
4.13. Statistical Analysis
BBB Scores, histological results (lesion volume and tissue sparing data), Western
blot measures, and Flow cytometry data were statistically analyzed using StatView (SAS
Institute, Cary, NC, USA). Data were presented as mean ± S.E.M. Group differences were
evaluated by repeated-measures ANOVA followed by the Bonferroni post hoc test (p < 0.05
was considered significant). The t-test was used to analyze differences between the two
groups.
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